<DOC>
	<DOCNO>NCT02948244</DOCNO>
	<brief_summary>This multi-centre , randomised , double-blind , placebo-controlled crossover trial compare change strength-related motor function follow treatment creatine monohydrate treatment placebo , measure Motor Function Measure , baseline 12 week . Eligible subject undergo baseline assessment randomise either creatine monohydrate therapy placebo three month , follow six week wash-out period , crossover three month therapy either placebo creatine . Subjects undergo clinical assessment study safety assessment begin end treatment period . The study begin recruitment early 2017 .</brief_summary>
	<brief_title>Effect Creatine Monohydrate Functional Muscle Strength Children With FSHD</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophy , Facioscapulohumeral</mesh_term>
	<criteria>Is age 5 18 year inclusive time randomisation ; Has confirm genetic diagnosis Facioscapulohumeral Muscular Dystrophy ( FSHD ) type 1 2 ; Has legally acceptable representative capable understanding inform consent document provide consent participant 's behalf . Has clinically significant elevation plasma creatinine level unexplained hypertension screening ; Has prior diagnosis chronic renal failure ; Has know hypersensitivity creatine monohydrate maltodextrin placebo ; Patients already take medication increase muscle bulk strength concomitant use regular sodium valproate , corticosteroid alpha agonist salbutamol .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>fshd</keyword>
	<keyword>creatine monohydrate</keyword>
	<keyword>child</keyword>
	<keyword>pediatrics</keyword>
	<keyword>Facio-Scapulo-Humeral Dystrophy</keyword>
</DOC>